Background and aims: In the ADHERE trial, subcutaneous (SC) efgartigimod PH20 (co‐formulated with recombinant human hyaluronidase PH20) reduced relapse rate and was well tolerated in chronic inflammatory demyelinating polyneuropathy (CIDP). This evidence concerns the gene SPAM1 and chronic inflammatory demyelinating polyradiculoneuropathy.